Twist Bioscience Stock

Twist Bioscience Equity

The The Equity of Twist Bioscience (TWST) as of Aug 13, 2026 is 472.96 M USD. In the previous year, The Equity was 472.69 M USD — a change of 0.06% (higher).

Equity

472.96 MUSD

YoY

0.06%

Last updated:

In 2026, Twist Bioscience's equity was 472.96 M USD, a 0.06% increase from the 472.69 M USD equity in the previous year.

Access this data via the Eulerpool API

Twist Bioscience Stock analysis

What does Twist Bioscience do? Twist Bioscience Corp is a company specializing in the production and applications of synthetic DNA. It was founded in 2013 and is based in San Francisco, California, USA. The company utilizes proprietary technologies to cost-effectively produce high-quality and high-quantity synthetic DNA. The company operates in three business areas: DNA synthesis, biopharmaceuticals, and data storage. The DNA synthesis division is the core of the company and involves the production of synthetic DNA for applications in various industries, including medicine, agricultural science, biotechnology, plastic engineering, and others. The company manufactures customized DNA synthesis products tailored to the needs of its customers, allowing them to accelerate and optimize their research and development projects. Twist Bioscience has also developed a proprietary technology called "Twist Biosensor" that enables rapid and cost-effective analysis of genetic variations. The biopharmaceutical division focuses on the development of therapeutics and diagnostics based on synthetic DNA. Twist Bioscience develops antibodies and proteins that can be used in cancer and immunotherapy, as well as diagnostics. In the data storage field, Twist Bioscience develops solutions for storing large amounts of data on DNA. This technology utilizes the dense and stable structure of DNA to securely and reliably store data in the long term. Twist Bioscience's DNA synthesis products are utilized by researchers, companies, and public institutions in various industries. Customers value not only the wide product portfolio but also the high quality and precision of the products, as well as the speed of order processing. The company operates a number of manufacturing facilities near its customers in Europe and Asia to ensure fast and efficient delivery of its products. This allows Twist Bioscience to have a strong position in the global market. In recent years, the company has achieved significant milestones. In 2018, Twist Bioscience went public and raised a total of $70 million through its IPO. The company has also established partnerships with various other companies and institutions to develop new applications and products. Overall, Twist Bioscience is a growing company specializing in the production and applications of synthetic DNA. With its wide range of high-quality and customized DNA synthesis products, as well as its innovative solutions in the biopharmaceutical and data storage sectors, the company has established a strong market position. Twist Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Twist Bioscience's Equity

Twist Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Twist Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Twist Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Twist Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Twist Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Twist Bioscience stock

The Equity of Twist Bioscience is 472.96 M USD in 2026.

The Equity of Twist Bioscience changed from 472.69 M USD to 472.96 M USD, representing a 0.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Twist Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Twist Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Twist Bioscience

All Key Metrics — Twist Bioscience